← back to search

Scott A. Armstrong

Harvard University · US
Area of research
Molecular Biology · Hematology
Research interest
Research interests include Acute Myeloid Leukemia Research, Protein Degradation and Inhibitors, Epigenetics and DNA Methylation, and Acute Lymphoblastic Leukemia research.
h-index
84
citations
36,532
works
613
NIH funding
primary concept
Biology
email

Recent publications

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions
International Journal of Cancer 2025cited by 16position: middledoi
Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia
Cancer Discovery 2025cited by 13position: middledoi
KAT6A and KAT7 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in <i>NUP98</i> -Rearranged Acute Myeloid Leukemia
Cancer Discovery 2025cited by 10position: middledoi
Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer
Cell Reports Medicine 2025cited by 8position: lastdoi
p300/CBP is an essential driver of pathogenic enhancer activity and gene expression in Ewing sarcoma
EMBO Reports 2025cited by 7position: lastdoi
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect
Cancer Research 2025cited by 3position: middledoi
PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway
Blood 2024cited by 28position: middledoi
Inherited blood cancer predisposition through altered transcription elongation
Cell 2024cited by 25position: middledoi
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Nature 2023cited by 450position: middledoi
MEN1 mutations mediate clinical resistance to menin inhibition
Nature 2023cited by 234position: middledoi
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Nature 2023cited by 101position: middledoi
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of <i>KMT2A</i>-r and <i>NPM1c</i> AML
Blood 2023cited by 26position: lastdoi
MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer
eLife 2023cited by 20position: middledoi
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia
Molecular Cancer 2023cited by 14position: middledoi
Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia
Cancer Discovery 2022cited by 121position: lastdoi
Antigen presentation safeguards the integrity of the hematopoietic stem cell pool
Cell stem cell 2022cited by 81position: middledoi
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia
Nature Cancer 2022cited by 56position: lastdoi
Epitope Engineered Hematopoietic Stem and Progenitor Cells to Enable CAR-T Cell Immunotherapy for Acute Myeloid Leukemia
Blood 2022cited by 6position: middledoi
The menin-MLL1 interaction is a molecular dependency in <i>NUP98</i>-rearranged AML
Blood 2021cited by 137position: lastdoi
Therapeutic targeting of preleukemia cells in a mouse model of <i>NPM1</i> mutant acute myeloid leukemia
Science 2020cited by 266position: lastdoi
Synergistic targeting of <i>FLT3</i> mutations in AML via combined menin-MLL and FLT3 inhibition
Blood 2020cited by 120position: middledoi
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition
Cancer Discovery 2020cited by 43position: lastdoi
Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination during Lymphoid Development
iScience 2020cited by 15position: lastdoi
A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies
Science 2019cited by 427position: middledoi
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Cancer Discovery 2019cited by 40position: middledoi
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
eLife 2018cited by 216position: lastdoi
A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response
Cell 2018cited by 124position: lastdoi
Peptidomimetic blockade of MYB in acute myeloid leukemia
Nature Communications 2018cited by 95position: middledoi
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia
Cancer Discovery 2018cited by 82position: middledoi
Author response: Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
2018cited by 5position: lastdoi

Grants

Coarse-graining, Renormalization, and Fractal Homogenization
NSF2350340$290,0552024–2027PIRePORTER
Renormalization in Statistical Mechanics and Partial Differential Equations
NSF1954357$359,9982020–2024PIRePORTER
Quantitative Stochastic Homogenization and Renormalization Methods
NSF2000200$340,0002020–2024PIRePORTER
Quantitative Methods for Modeling Properties of Random Media
NSF1700329$180,0002017–2020PIRePORTER
PostDoctoral Research Fellowship
NSF1004645$135,0002010–2014PIRePORTER

Frequent collaborators

· 8 papers (2012–2025)Richard P. Koche · New York Proton Center8 papers (2015–2023)Charlie Hatton · Dana-Farber Cancer Institute7 papers (2020–2025)Gerard M. McGeehan · Eloxx Pharmaceuticals (United States)6 papers (2020–2023)Chun‐Wei Chen · Toyota Motor Corporation (Switzerland)6 papers (2016–2023)Florian Perner · Universitätsmedizin Greifswald6 papers (2021–2025)Yanhe Wen · Dana-Farber Cancer Institute5 papers (2021–2025)Amit Sinha · University of Massachusetts Chan Medical School5 papers (2012–2016)Nan Zhu · J. Craig Venter Institute4 papers (2012–2015)Benjamin L. Ebert · Harvard University4 papers (2014–2025)S. Haihua Chu · National Yang Ming Chiao Tung University4 papers (2017–2020)Yana Pikman · Harvard University4 papers (2019–2023)James E. Bradner · Novartis (China)4 papers (2016–2018) · 3 papers (2022–2025) · 3 papers (2016–2018)George S. Vassiliou · Wellcome/MRC Cambridge Stem Cell Institute3 papers (2016–2020)Hannah J. Uckelmann · Goethe University Frankfurt3 papers (2020–2022)Wallace Bourgeois · New York University3 papers (2022–2025) · 3 papers (2017–2018)Lars Bullinger · University of Gothenburg3 papers (2012–2020)